|
Real-time Estimate
Tradegate
12:38:59 22/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 58.95 EUR | +0.17% |
|
+2.71% | -7.32% |
| 23/07 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| 23/07 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
Company Valuation: Laboratorios Farmaceuticos Rovi, S.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,138 | 1,925 | 3,213 | 3,220 | 3,248 | 3,010 | - | - |
| Change | - | -53.49% | 66.93% | 0.22% | 0.87% | -7.33% | - | - |
| Enterprise Value (EV) 1 | 4,112 | 1,872 | 3,251 | 3,305 | 3,272 | 3,001 | 2,937 | 2,824 |
| Change | - | -54.48% | 73.7% | 1.65% | -1% | -8.27% | -2.13% | -3.85% |
| P/E | 26.7x | 9.67x | 18.8x | 23.6x | 23.1x | 19.9x | 17.5x | 14.1x |
| PBR | 8.59x | 3.71x | 5.94x | 5.63x | 4.89x | 4x | 3.42x | 2.93x |
| PEG | - | 0.3x | -1.3x | -1.4x | 7.71x | 2.6x | 1.3x | 0.6x |
| Capitalization / Revenue | 6.38x | 2.35x | 3.87x | 4.22x | 4.37x | 3.89x | 3.37x | 3.08x |
| EV / Revenue | 6.34x | 2.29x | 3.92x | 4.33x | 4.4x | 3.88x | 3.29x | 2.89x |
| EV / EBITDA | 20.3x | 6.72x | 13.3x | 15.9x | 15.1x | 15.2x | 11.4x | 9.04x |
| EV / EBIT | 22.7x | 7.32x | 14.8x | 18.4x | 17.6x | 18.3x | 13.2x | 10.2x |
| EV / FCF | 37.9x | 10.1x | 54.3x | 43.5x | 27.4x | 23.9x | 24x | 17x |
| FCF Yield | 2.64% | 9.95% | 1.84% | 2.3% | 3.65% | 4.19% | 4.17% | 5.88% |
| Dividend per Share 2 | 0.9556 | 1.294 | 1.104 | 0.9351 | 0.9594 | 0.9737 | 1.161 | 1.361 |
| Rate of return | 1.29% | 3.59% | 1.83% | 1.49% | 1.51% | 1.65% | 1.97% | 2.31% |
| EPS 2 | 2.76 | 3.73 | 3.2 | 2.67 | 2.75 | 2.96 | 3.37 | 4.164 |
| Distribution rate | 34.6% | 34.7% | 34.5% | 35% | 34.9% | 32.9% | 34.5% | 32.7% |
| Net sales 1 | 648.7 | 817.7 | 829.5 | 763.7 | 743.5 | 774.1 | 892.4 | 978 |
| EBITDA 1 | 202.9 | 278.7 | 244.5 | 207.4 | 216.2 | 197.6 | 257.3 | 312.3 |
| EBIT 1 | 181.5 | 255.8 | 220.1 | 179.4 | 185.8 | 164.4 | 222.4 | 275.8 |
| Net income 1 | 153.1 | 199.7 | 170.3 | 136.9 | 140.4 | 146.2 | 172.9 | 213.8 |
| Net Debt 1 | -25.87 | -52.78 | 38.6 | 85.1 | 23.84 | -8.499 | -72.51 | -185.6 |
| Reference price 2 | 73.80 | 36.06 | 60.20 | 62.95 | 63.50 | 58.85 | 58.85 | 58.85 |
| Nbr of stocks (in thousands) | 56,069 | 53,375 | 53,370 | 51,149 | 51,149 | 51,143 | - | - |
| Announcement Date | 23/02/22 | 21/02/23 | 27/02/24 | 25/02/25 | 24/02/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.88x | 3.88x | 15.19x | 1.65% | 345.2Cr | |
| 33.12x | 12.04x | 24.4x | 0.6% | 1,03800Cr | |
| 29.97x | 6.67x | 18.66x | 1.99% | 65TCr | |
| 33.44x | 7.83x | 16.17x | 2.59% | 47TCr | |
| 19.76x | 4.83x | 11.96x | 2.74% | 36TCr | |
| 19.95x | 5.21x | 12.92x | 3.08% | 27TCr | |
| 21.41x | 4.44x | 12.62x | 1.99% | 26TCr | |
| 24.9x | 6.52x | 11.62x | 2.57% | 21TCr | |
| 11.64x | 4.24x | 8.76x | 4.32% | 18TCr | |
| -45.54x | 6.63x | 25.88x | 2.19% | 19TCr | |
| Average | 16.86x | 6.23x | 15.82x | 2.37% | 36.19TCr | |
| Weighted average by Cap. | 23.87x | 7.78x | 17.94x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROVI Stock
- Valuation Laboratorios Farmaceuticos Rovi, S.A.
Select your edition
All financial news and data tailored to specific country editions
